Logo image of 6IV.DE

INVENTIVA SA (6IV.DE) Stock Fundamental Analysis

Europe - Frankfurt Stock Exchange - FRA:6IV - FR0013233012 - Common Stock

5.04 EUR
+0.67 (+15.33%)
Last: 1/14/2026, 7:00:00 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to 6IV. 6IV was compared to 83 industry peers in the Biotechnology industry. 6IV has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, 6IV is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • 6IV had negative earnings in the past year.
  • 6IV had a negative operating cash flow in the past year.
  • 6IV had negative earnings in each of the past 5 years.
  • 6IV had a negative operating cash flow in each of the past 5 years.
6IV.DE Yearly Net Income VS EBIT VS OCF VS FCF6IV.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

  • 6IV has a worse Return On Assets (-173.72%) than 83.13% of its industry peers.
Industry RankSector Rank
ROA -173.72%
ROE N/A
ROIC N/A
ROA(3y)-120.12%
ROA(5y)-85.05%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
6IV.DE Yearly ROA, ROE, ROIC6IV.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K

1.3 Margins

  • 6IV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
6IV.DE Yearly Profit, Operating, Gross Margins6IV.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K

More info and screens

3

2. Health

2.1 Basic Checks

  • 6IV does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, 6IV has more shares outstanding
  • The number of shares outstanding for 6IV has been increased compared to 5 years ago.
  • 6IV has a better debt/assets ratio than last year.
6IV.DE Yearly Shares Outstanding6IV.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
6IV.DE Yearly Total Debt VS Total Assets6IV.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of -0.92, we must say that 6IV is in the distress zone and has some risk of bankruptcy.
  • 6IV's Altman-Z score of -0.92 is in line compared to the rest of the industry. 6IV outperforms 42.17% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -0.92
ROIC/WACCN/A
WACC7.87%
6IV.DE Yearly LT Debt VS Equity VS FCF6IV.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

2.3 Liquidity

  • A Current Ratio of 2.96 indicates that 6IV has no problem at all paying its short term obligations.
  • 6IV's Current ratio of 2.96 is fine compared to the rest of the industry. 6IV outperforms 61.45% of its industry peers.
  • 6IV has a Quick Ratio of 2.96. This indicates that 6IV is financially healthy and has no problem in meeting its short term obligations.
  • 6IV's Quick ratio of 2.96 is fine compared to the rest of the industry. 6IV outperforms 66.27% of its industry peers.
Industry RankSector Rank
Current Ratio 2.96
Quick Ratio 2.96
6IV.DE Yearly Current Assets VS Current Liabilites6IV.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

  • 6IV shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -74.11%.
  • 6IV shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -12.84%.
  • The Revenue has been growing slightly by 5.62% on average over the past years.
EPS 1Y (TTM)-74.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-71.33%
Revenue 1Y (TTM)-12.84%
Revenue growth 3Y29.92%
Revenue growth 5Y5.62%
Sales Q2Q%10763.41%

3.2 Future

  • Based on estimates for the next years, 6IV will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.92% on average per year.
  • The Revenue is expected to grow by 123.15% on average over the next years. This is a very strong growth
EPS Next Y44.75%
EPS Next 2Y24.76%
EPS Next 3Y14.52%
EPS Next 5Y15.92%
Revenue Next Year1.86%
Revenue Next 2Y-43.78%
Revenue Next 3Y54.3%
Revenue Next 5Y123.15%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
6IV.DE Yearly Revenue VS Estimates6IV.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B
6IV.DE Yearly EPS VS Estimates6IV.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for 6IV. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for 6IV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
6IV.DE Price Earnings VS Forward Price Earnings6IV.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
6IV.DE Per share data6IV.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

  • 6IV's earnings are expected to grow with 14.52% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.76%
EPS Next 3Y14.52%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for 6IV!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

INVENTIVA SA

FRA:6IV (1/14/2026, 7:00:00 PM)

5.04

+0.67 (+15.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-21
Earnings (Next)02-16
Inst Owners43.32%
Inst Owner ChangeN/A
Ins Owners4.97%
Ins Owner ChangeN/A
Market Cap962.73M
Revenue(TTM)13.61M
Net Income(TTM)-310.88M
Analysts87.14
Price Target12.16 (141.27%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)1.72%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)19.96%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 70.73
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.62
EYN/A
EPS(NY)-0.99
Fwd EYN/A
FCF(TTM)-0.48
FCFYN/A
OCF(TTM)-0.48
OCFYN/A
SpS0.07
BVpS-0.05
TBVpS-0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -173.72%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-120.12%
ROA(5y)-85.05%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.71%
Cap/Sales 0.93%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.96
Quick Ratio 2.96
Altman-Z -0.92
F-Score4
WACC7.87%
ROIC/WACCN/A
Cap/Depr(3y)20.07%
Cap/Depr(5y)N/A
Cap/Sales(3y)3.77%
Cap/Sales(5y)20.51%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-74.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-71.33%
EPS Next Y44.75%
EPS Next 2Y24.76%
EPS Next 3Y14.52%
EPS Next 5Y15.92%
Revenue 1Y (TTM)-12.84%
Revenue growth 3Y29.92%
Revenue growth 5Y5.62%
Sales Q2Q%10763.41%
Revenue Next Year1.86%
Revenue Next 2Y-43.78%
Revenue Next 3Y54.3%
Revenue Next 5Y123.15%
EBIT growth 1Y2.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year8.14%
EBIT Next 3Y3.93%
EBIT Next 5Y22.65%
FCF growth 1Y-42.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-43.45%
OCF growth 3YN/A
OCF growth 5YN/A

INVENTIVA SA / 6IV.DE FAQ

Can you provide the ChartMill fundamental rating for INVENTIVA SA?

ChartMill assigns a fundamental rating of 2 / 10 to 6IV.DE.


What is the valuation status of INVENTIVA SA (6IV.DE) stock?

ChartMill assigns a valuation rating of 0 / 10 to INVENTIVA SA (6IV.DE). This can be considered as Overvalued.


What is the profitability of 6IV stock?

INVENTIVA SA (6IV.DE) has a profitability rating of 0 / 10.


How financially healthy is INVENTIVA SA?

The financial health rating of INVENTIVA SA (6IV.DE) is 3 / 10.